236 documents

Read All
22:45 , Apr 12, 2019 |  BioCentury  |  Emerging Company Profile

Bright Angel: New hope against fungal resistance

Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance...
Read More
18:58 , Feb 1, 2019 |  BioCentury  |  Finance

Discovering Dewpoint's protein organizers

An experienced team and a drug discovery platform targeting biomolecular condensates enabled Dewpoint Therapeutics to raise $60 million in a series A round led by founding investor Polaris Partners. Samsara BioCapital, 6 Dimensions Capital, EcoR1...
Read More
21:59 , Dec 6, 2018 |  BC Week In Review  |  Clinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
Read More
23:59 , Dec 4, 2018 |  BC Extra  |  Preclinical News

Yumanity reveals Parkinson's candidate as first compound from yeast platform

Yumanity Therapeutics LLC (Cambridge, Mass.) and colleagues used the company's yeast platform to identify inhibitors of the enzyme stearoyl-CoA desaturase-1 (SCD1) that could prevent α-synuclein toxicity in Parkinson's disease. The SCD1 inhibitors are the first...
Read More
11:26 , Sep 28, 2018 |  BC Extra  |  Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
Read More
01:50 , Sep 14, 2018 |  BC Innovations  |  Targets & Mechanisms

Repeat offenders

Dozens of intractable DNA repeat-driven diseases could boil down to a common problem: disrupted boundaries between chromatin domains, according to a study from the University of Pennsylvania. The results present new opportunities for diseases like...
Read More
00:52 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

RNA party

A study in Cell has uncovered a brain regulatory network involving a circular RNA, a long non-coding RNA and two microRNAs, and could provide some much needed insights in a field where finding links to...
Read More
19:31 , Jun 1, 2018 |  BC Week In Review  |  Financial News

CAMP4 Therapeutics launches with $30M series A

CAMP4 Therapeutics Corp. (Cambridge, Mass.) launched on May 31 with an untranched $30 million series A round led by new investor Andreessen Horowitz. Existing investors The Kraft Group and Polaris Partners also participated. A CAMP4...
Read More
12:31 , May 31, 2018 |  BC Extra  |  Financial News

CAMP4 Therapeutics launches with $30M series A

CAMP4 Therapeutics Corp. (Cambridge, Mass.) launched with an untranched $30 million series A round led by new investor Andreessen Horowitz. Existing investors The Kraft Group and Polaris Partners also participated. A CAMP4 spokesperson told BioCentury...
Read More
23:23 , May 4, 2018 |  BC Extra  |  Preclinical News

PPAR agonist-induced fatty acid metabolism boosts tissue regeneration

Scientists at the Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology published a paper in Cell Stem Cell showing that fatty acid oxidation (FAO) induced by short-term fasting promotes tissue regeneration and repair,...
Read More